title: Intravesical Bacillus Calmette-Guerin for treating bladder cancer.
abstract: Bladder cancer continues to be a leading cause of malignant neoplasm in men. Since 1976, Bacillus Calmette-Guerin (BCG) has been a recommended treatment for superficial bladder malignancy. BCG treatment indications, administration, side effects, patient education, and nursing implications are discussed.
authors.affiliation: Southwest Florida Urologic Associates, Cape Coral, FL, USA.
authors.forename: Lee Ann
authors.initials: LA
authors.lastname: Boyd
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000283:Administration, Intravesical; D001500:BCG Vaccine / Q000008:administration & dosage*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology / Q000601:surgery; D000075202:Contraindications; D006801:Humans; D008297:Male; D008875:Middle Aged; D024802:Nurse's Role; D010353:Patient Education as Topic; D018579:Patient Selection; D012307:Risk Factors; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology / Q000601:surgery
chemical_list: D000276:Adjuvants, Immunologic; D001500:BCG Vaccine